Leerink Partnrs Weighs in on Immunome, Inc.’s Q1 2024 Earnings (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ:IMNM) – Leerink Partnrs lifted their Q1 2024 EPS estimates for Immunome in a research note issued to investors on Tuesday, March 26th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($1.71) for the quarter, up from their prior forecast of ($2.21). Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Immunome’s current full-year earnings is ($0.97) per share. Leerink Partnrs also issued estimates for Immunome’s Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.18) EPS, Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($2.17) EPS, FY2025 earnings at ($2.29) EPS and FY2026 earnings at ($2.90) EPS.

A number of other research analysts have also recently weighed in on the stock. SVB Leerink started coverage on shares of Immunome in a report on Monday, January 29th. They issued an “outperform” rating and a $30.00 price objective for the company. Wedbush lifted their price objective on shares of Immunome from $12.00 to $19.00 and gave the company an “outperform” rating in a report on Tuesday, January 23rd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Immunome presently has an average rating of “Buy” and a consensus price target of $24.50.

Immunome Stock Performance

Shares of IMNM stock opened at $24.68 on Friday. The company has a 50 day moving average price of $22.31 and a 200 day moving average price of $13.48. Immunome has a fifty-two week low of $4.44 and a fifty-two week high of $30.96.

Institutional Trading of Immunome

Several institutional investors have recently modified their holdings of the stock. Royal Bank of Canada raised its position in Immunome by 3.2% in the 4th quarter. Royal Bank of Canada now owns 29,484 shares of the company’s stock valued at $315,000 after purchasing an additional 928 shares during the last quarter. BlackRock Inc. raised its position in Immunome by 4.3% in the 2nd quarter. BlackRock Inc. now owns 43,312 shares of the company’s stock valued at $343,000 after purchasing an additional 1,773 shares during the last quarter. HighTower Advisors LLC increased its stake in Immunome by 19.0% in the 3rd quarter. HighTower Advisors LLC now owns 18,818 shares of the company’s stock valued at $157,000 after buying an additional 3,000 shares during the period. Dorsey Wright & Associates acquired a new position in Immunome in the 3rd quarter valued at $26,000. Finally, Vanguard Group Inc. increased its stake in Immunome by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 373,685 shares of the company’s stock valued at $1,659,000 after buying an additional 3,149 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.